Neurotherapeutics. 2016 Jan;13(1):70-83. doi: 10.1007/s13311-015-0400-8. Kleiter I, Gold R. Neuromyelitis optica spectrum disorders (NMOSD) are important evolving entities, which have reached much attention in the…
J Clin Neurol. 2013 Jan;9(1):36-42. doi: 10.3988/jcn.2013.9.1.36. Epub 2013 Jan 3. Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ. Source Department of Neurology, Research Institute and Hospital…
Treatment of neuromyelitis optica: an evidence based review.
Neuromyelitis optica (NMO, Devic’s disease), an uncommon demyelinating neuro-immunological disease, can be associated with autoimmune diseases. In SLE associated forms anti-aquaporin-4 antibody positivity can help differentiating between SLE nerve system manifestation and NMO.
Recurrent attacks of optic neuritis and myelitis are the hallmarks of both neuromyelitis optica (NMO) and multiple sclerosis (MS). NMO immunoglobulin G (NMO-IgG), which recognizes astrocytic aquaporin-4 (AQP4) water channels, is a specific serum autoantibody that distinguishes NMO from MS. The pathogenic role of the anti-AQP4 antibody (AQP4-Ab, NMO-IgG) in NMO has been speculated based on several studies in vitro.
A 29-YEAR-OLD WOMAN of Afro-Caribbean descent with a history of thyrotoxicosis was evaluated for right leg weakness and diagnosed as having myelitis.
Neuromyelitis optica (NMO), characterised by longitudinally extensive transverse myelitis (LETM), was previously thought to be a variant of multiple sclerosis.
Neuromyelitis optica (NMO) or Devic’s disease is an uncommon idiopathic demyelinating disease of the central nervous system with selective involvement of the optic nerves and spinal cord. There are no scientifically proven guidelines on treatment of this condition either in the acute attacks or on a long-term basis.